---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-24-000093"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:40:02.503987+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027

## Summary
- Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.
- Cash, cash equivalents & marketable securities $327M as of Sept 30, 2024; expected to fund operations into H1 2027.
- Phase 3 PROSERA trial in PAH enrollment ongoing; topline results expected Q4 2025.
- Expect to commence global registrational Phase 3 trial for PH-ILD in mid-2025.
- R&D expenses $34.9M (up from $31.2M); G&A $8.5M (down from $9.3M) YoY.

## SEC filing metadata
- accession: 0001728117-24-000093
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000093/0001728117-24-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811724000093/goss-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-24-000093
- JSON: https://secwatch.observer/filing/0001728117-24-000093.json
- Plain text: https://secwatch.observer/filing/0001728117-24-000093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.